Search

Your search keyword '"Wong, Kwok"' showing total 123 results

Search Constraints

Start Over You searched for: Author "Wong, Kwok" Remove constraint Author: "Wong, Kwok" Publication Year Range This year Remove constraint Publication Year Range: This year
123 results on '"Wong, Kwok"'

Search Results

1. Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

4. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

8. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression

10. Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients.

11. Array-based specific classification of bacterial species via hydrophilic/hydrophobic biosensors.

12. Supplementary Figure S9 from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

13. Supplementary Tables from Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

14. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

15. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

16. Supplementary Table 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

17. FIGURE 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

18. Supplementary Figure 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

19. FIGURE 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

20. FIGURE 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

21. Supplementary Figure 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

22. Supplementary Table 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

24. Supplementary Figure 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

25. FIGURE 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

26. Supplementary Table 4 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

27. Supplementary Table 2 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

28. Supplementary Figure 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

29. Supplementary Table 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

30. Supplementary Table 6 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

31. FIGURE 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

32. Supplementary Figure 1 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

33. FIGURE 3 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

34. Supplementary Figure 5 from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

35. Data from EZH2 Inhibition Promotes Tumor Immunogenicity in Lung Squamous Cell Carcinomas

36. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

37. EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas

38. Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?

39. Quasi-Projective Manifolds Uniformized by Carathéodory Hyperbolic Manifolds and Hyperbolicity of Their Subvarieties.

40. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

41. Treatment-related Complications in Children with Cancer

42. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation

43. Enhanced Activity against Multidrug-Resistant Bacteria through Coapplication of an Analogue of Tachyplesin I and an Inhibitor of the QseC/B Signaling Pathway

44. Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.

45. Characterization of tumor heterogeneity through segmentation-free representation learning.

46. Deconvolution of the tumor-educated platelet transcriptome reveals activated platelet and inflammatory cell transcript signatures.

47. CORR Insights®: Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.

48. Apathy in subarachnoid hemorrhage: study protocol for a 1-year follow-up study.

49. Controversies in orthopaedic oncology.

50. Spatial engineering of single-atom Fe adjacent to Cu-assisted nanozymes for biomimetic O 2 activation.

Catalog

Books, media, physical & digital resources